Suchergebnisse - "van de Loosdrecht, A A"

PubPharm (133)

1

Determinants of lenalidomide response with or without erythropoiesis-stimulating agents in myelodysplastic syndromes : the HOVON89 trial

enthalten in: Leukemia | 2024

von van de Loosdrecht, A. | Cremers, E. | Alhan, C. | +37

2

Age and sex associate with outcome in older AML and high risk MDS patients treated with 10-day decitabine

enthalten in: Blood cancer journal | 2023

von Hilberink, J. | van Zeventer, I. | Chitu, D. | +54

3

Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS

enthalten in: Leukemia | 2021

von Kuendgen, A. | Nomdedeu, M. | Tuechler, H. | +47

4

Use of azacitidine and its safety and efficacy in daily clinical practice in The Netherlands : the OCEAN study

enthalten in: Leukemia & lymphoma | 2020

von Cruijsen, M. | van der Velden, W. | de Haan, A. | +13

5

Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials

enthalten in: Blood | 2019

von Platzbecker, U. | Fenaux, P. | Adès, L. | +13

6

Erythropoiesis-stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower-risk myelodysplastic syndrome

enthalten in: Journal of internal medicine | 2017

von Garelius, H. | Johnston, W. | Smith, A. | +15

7

Response to letter commenting on : Prognostic relevance of morphological classification models for myelodysplastic syndromes in an era of the revised International Prognostic Scoring System

enthalten in: European journal of cancer (Oxford, England : 1990) | 2017

von van Spronsen, M. | Witte, B. | Ossenkoppele, G. | +2

CommentOn: Eur J Cancer. 2016 Mar;56:10-20. - PMID 26798967

8

Erythropoiesis‐stimulating agents significantly delay the onset of a regular transfusion need in nontransfused patients with lower‐risk myelodysplastic syndrome

enthalten in: Journal of internal medicine / Supplement | 2017

von Garelius, H. | Johnston, W. | Smith, A. | +15

9

Massive parallel RNA sequencing of highly purified mesenchymal elements in low-risk MDS reveals tissue-context-dependent activation of inflammatory programs

enthalten in: Leukemia | 2016

von Chen, S. | Zambetti, N. | Bindels, E. | +10

10

Effectiveness of azacitidine in higher-risk myelodysplastic syndromes

enthalten in: Leukemia | 2016

von Dinmohamed, A. | van Norden, Y. | van de Loosdrecht, A. | +1

CommentOn: Leukemia. 2015 Dec;29(12):2449-51. - PMID 26369829

1
2
3
4
5
6
7
8
9
10
11
Nächster »
[14]